TY - JOUR
T1 - Reduced Haloperidol/Haloperidol ratio and clinical outcome in schizophrenia
T2 - Preliminary evidences
AU - Altamura, Carlo
AU - Mauri, Massimo
AU - Cavallaro, Roberto
AU - Colacurcio, Fulgenzio
AU - Gorni, Alfredo
AU - Bareggi, Silvio
PY - 1988
Y1 - 1988
N2 - 1. 1. The possible influence of haloparidol and its metabolite plasma levels on clinical outcome in schizophrenic patients was evaluated. 2. 2. 18 schizophrenic inpatients diagnosed according to DSM III, were treated with conventional haioperidol p.o. for four weeks. 3. 3. Plasma levels of haloperidol and its reduced metabolite were measured by massspectrometry assay. Clinical outcome was evaluated by BPRS, 4. 4. Cluster analysis only considering BPRS improvement and reduced haloperidol/haloperidol ratio was'able to discriminate two groups of patients: one of non responders and the other of responders. The former group presented higher ratios than the latter. 5. 5. Reduced haloperidol/haloperidol ratio could be considered as a good marker for prediction of the clinical outcome.
AB - 1. 1. The possible influence of haloparidol and its metabolite plasma levels on clinical outcome in schizophrenic patients was evaluated. 2. 2. 18 schizophrenic inpatients diagnosed according to DSM III, were treated with conventional haioperidol p.o. for four weeks. 3. 3. Plasma levels of haloperidol and its reduced metabolite were measured by massspectrometry assay. Clinical outcome was evaluated by BPRS, 4. 4. Cluster analysis only considering BPRS improvement and reduced haloperidol/haloperidol ratio was'able to discriminate two groups of patients: one of non responders and the other of responders. The former group presented higher ratios than the latter. 5. 5. Reduced haloperidol/haloperidol ratio could be considered as a good marker for prediction of the clinical outcome.
KW - clinical outcome
KW - reduced haloperidol
KW - schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=0023722929&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023722929&partnerID=8YFLogxK
U2 - 10.1016/0278-5846(88)90013-9
DO - 10.1016/0278-5846(88)90013-9
M3 - Article
C2 - 3222450
AN - SCOPUS:0023722929
VL - 12
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
SN - 0278-5846
IS - 5
ER -